Study shows promise of precision medicine for most common type of lymphoma

20 julio 2015

Patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease, a new study shows.img src=»» height=»1″ width=»1″ alt=»»/